SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	7,917,470	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	-12.09%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	7,788,689	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	101100.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	30.93	36.14	-	-	117.39	-
Forward PE	40.26	73.81	-	-	-	-
PS Ratio	12.76	15.89	22.16	22.94	18.18	509.06
PB Ratio	12.89	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	13.49	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	78.39	93.05	-	-	-	-
P/OCF Ratio	76.70	91.68	-	-	-	-
EV/Sales Ratio	12.56	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	61.30	75.93	-	-	68.18	-
EV/EBIT Ratio	71.24	89.66	-	-	76.53	-
EV/FCF Ratio	77.12	92.38	-	-	-	-
Debt / Equity Ratio	0.12	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.45	1.62	-	-	0.15	-
Debt / FCF Ratio	0.74	1.97	-	-	-	-
Asset Turnover	0.70	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.36	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.54	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.19	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	49.08%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	10.38%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Capital (ROIC)	14.56%	9.58%	-4.83%	-17.57%	13.84%	-60.65%
Return on Capital Employed (ROCE)	21.40%	15.00%	-	-	19.20%	-
Earnings Yield	3.23%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.28%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.